© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Sydney Jennings
Articles
Upstream Bio's TSLP Antagonist Verekitug Enters Global Phase 2 Trial for COPD
July 11, 2025
Verekitug is the only biologic in development for COPD that targets the TSLP receptor directly.
Tralokinumab Update: Positive 16-Week Interim Results Reported for ADHAND Trial in Adults with Hand Eczema
July 11, 2025
Tralokinumab met key trial endpoints with no new safety signals in treatment of moderate-to-severe hand eczema, in adults who are candidates for systemic therapy.
Obesity and Chronic Pain: Monu Khanna, MD, on Breaking the Vicious Cycle
July 10, 2025
Dr Khanna breaks down the bidirectional relationship and explains why standard pain management often falls short for people with obesity.
Real-World Data Highlight Impact of Treatment Discontinuation on Obesity Pharmacotherapy Outcomes
July 10, 2025
A recent study highlights the importance of medication adherence for significant weight loss and improved glycemic control in obesity treatment with GLP-1 agonists.
Adult Vaccines in the US: More Shots, New Dynamics on the Horizon
July 10, 2025
The adult vaccine market is poised for explosive growth, with more than 100 product launches expected over the next 10 years. Are US clinicians ready?
FDA Grants Full Approval of Moderna’s COVID-19 Vaccine for High-Risk Children Aged 6 Months to 11 Years
July 10, 2025
Moderna’s Spikevax receives full FDA approval for use in children at increased risk for COVID-19, expanding protection ahead of the 2025–2026 virus season.
Investigational Rapid-Acting PTSD Medication Awarded FDA Breakthrough Therapy Status: Transcend Therapeutics Update
July 10, 2025
TSND-201, a rapid-acting neuroplastogen, demonstrated statistically significant symptom improvement by day 10, which was durable throughout the study until Day 64.
Pain Management in Patients with Obesity: Clinician Insights on Balancing Pharmacological & Lifestyle Approaches
July 09, 2025
Monu Khanna, MD, discusses common medications, non-drug strategies, and holistic approaches to improve outcomes.
Donanemab Label Revised: New Dosing Schedule Approved for Early Alzheimer’s Treatment
July 09, 2025
The adjusted dosing for donanemab in early AD reduced ARIA-E risk by 41% compared to the original dosing, without compromising efficacy.
Quest Will Offer FDA-Cleared Fujirebio Blood Test to Detect Alzheimer Disease
July 09, 2025
The Fujirebio in-vitro diagnostic has shown positive and negative predictive values of 92% and 97%, respectively, for early AD detection and will be offered by end of summer.